68Ga标记药物研究进展

doi:10.7538/tws.2018.youxian.023

摘要/Abstract

摘要：

正电子发射型计算机断层显像(positron emission tomography, PET)是核医学领域重要的诊断及显像工具，在基础医学诊断、新药研发和疗效评价等各方面发挥越来越重要作用。¹⁸F是PET显像最常用的核素，但¹⁸F需要加速器生产。⁶⁸Ga为PET显像核素，可以从长寿命的⁶⁸Ge/⁶⁸Ga发生器装置获得，不必依赖加速器。随着配位化学的发展，各种双功能螯合剂用于⁶⁸Ga的标记，可将⁶⁸Ga与多种化学结构及生物分子连接并且可以药盒化⁶⁸Ga标记药物。本文主要介绍近期⁶⁸Ga标记放射性药物的研究进展。

关键词: PET显像, ⁶⁸Ga发生器, ⁶⁸Ga标记药物

Abstract:

Positron emission tomography (PET) is an important diagnosis and imaging tool for nuclear medicine, and playing an increasing part in fundamental medicine, new drug research and clinical effect assessment, etc. ¹⁸F is the most common radionuclide for PET imaging, which is produced in a cyclotron. ⁶⁸Ga is a PET imaging radionuclide of increasing concern, and is gained from long-lived ⁶⁸Ge/⁶⁸Ga generator systems. The use of ⁶⁸Ga does not demandan on-site cyclotron, which provide a convenient method for researchers. With the development of coordination chemistry, a variety of bifunctional chelators have been developed for ⁶⁸Ga labeling, which allow the convenient coupling tomany chemical structures and biomolecules. Kitformulated preparation is another advantage for ⁶⁸Ga radiopharmaceuticals. This review presents the developments of the ⁶⁸Ga based radiopharmaceuticals.

Key words: positron emission tomography, ⁶⁸Ga generator, ⁶⁸Ga radiopharmaceuticals

郭志德;张现忠;杜进. ⁶⁸Ga标记药物研究进展[J]. 同位素, 2019, 32(5): 360-374.

GUO Zhide;ZHANG Xianzhong;DU Jin. The Research Progress of ⁶⁸Ga Generator and ⁶⁸Ga Radiopharmaceuticals[J]. Journal of Isotopes, 2019, 32(5): 360-374.

参考文献

［1］Lau J, Zhang Z, Jenni S, et al. PET imaging of carbonic anhydrase IX expression of HT-29 tumor xenograft mice with ⁶⁸Ga-labeled benzene sulfonamides［J］. Molecular Pharmaceutics, 2016, 13(3): 1137-1146.
［2］Dimitrakopouloustrauss A. PET-based molecular imaging in personalized oncology: potential of the assessment of therapeutic outcome［J］. Future Oncology, 2015, 11(7): 1083-1091.
［3］Tan E H, Goh S W. Exploring new frontiers in molecular imaging: Emergence of Ga PET/CT［J］. World Journal of Radiology, 2010, 2: 55-67.
［4］Anger H O, Gottschalk A. Localization of brain tumors with the positron scintillation camera［J］. Journal of Nuclear Medicine, 1963, 4: 326-330.
［5］Ido T, Wan C N, Casella V. Labeled 2-deoxy-D-glucose analogs: ¹⁸F-labeled 2-deoxy-2-fluoro-D-mannose, and 14C-2-deoxy-2-fluoro-D-glucose［J］. Journal of Labelled Compounds & Radiopharmaceuticals, 1978, 14: 175-183.
［6］Banerjee S R, Pomper M G. Clinical applications of gallium-68［J］. Applied Radiation & Isotopes, 2013, 76: 2-13.
［7］Maecke H R, Hofmann M, Haberkorn U. ⁶⁸Ga labeled peptides in tumor imaging［J］. Journal of Nuclear Medicine, 2005, 46(Suppl 1): 172S-178S.
［8］Gleason G I. A positron cow［J］. International Journal of Applied Radiation & Isotopes, 1960, 8: 90-94.
［9］Kopeck Y＇ P, Mudrová B, Svoboda K. The study of conditions for the preparation and utilization of ⁶⁸Ge/⁶⁸Ga generator［J］. International Journal of Applied Radiation& Isotopes, 1973, 24: 73-80.
［10］王中央,范我,牛芳,等. 锗-68-镓-68同位素发生器［J］. 原子能科学技术,1980,22(2):183-183.Wang zhongyang, Fan Wo, Niu Fang, et al. ⁶⁸Ge/⁶⁸Ga generators［J］. Atomic Energy Science and Technology, 1980, 22(2): 183-183(in Chinese).
［11］Velikyan I. ⁶⁸Ga Based radiopharmaceuticals: production and application relationship［J］. Molecules, 2015, 20: 12913-12943.
［12］Ferreira C L, Yapp D T, Mandel D, et al. ⁶⁸Ga small peptide imaging: comparison of NOTA and PCTA［J］. Bioconjugate Chemistry, 2012, 23: 2239-2246.
［13］Boros E, Ferreira C L, Cawthray J F, et al. Acyclic chelate with ideal properties for ⁶⁸Ga PET imaging agent elaboration［J］. Journal of the American Chemical Society, 2010, 132: 15726-15733.
［14］Dumont R A, Deininger F, Haubner R, et al. Novel ⁶⁴Cu and ⁶⁸Ga-labeled RGD conjugates show improved PET imaging of 3 integrin expression and facile radiosynthesis［J］. Journal of Nuclear Medicine, 2011, 52: 1276-1284.
［15］Knetsch P A, Petrik M, Griessinger C M, et al. ［⁶⁸Ga］NODAGA-RGD for imaging α_vβ₃ integrin expression［J］. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38: 1303-1312.
［16］Velikyan I, Maecke H, Langstrom B. Convenient preparation of ⁶⁸Ga-Based PET-radiopharmaceuticals at room temperature［J］. Bioconjugate Chemistry, 2008, 19: 569-573.
［17］Jakub Š, Hermann P, Wester H J, et al. How is ⁶⁸Ga labeling of macrocyclic chelators influenced by metal ion contaminants in ⁶⁸Ge/⁶⁸Ga generator eluates?［J］. Chemmedchem, 2013, 8: 95-103.
［18］陈文,魏洪源,周志军,等. 金属正电子核素⁶⁴Cu,⁶⁸Ga, ⁸⁶Y, ⁸⁹Zr的PET标记药物研究进展［J］. 同位素,2017,30(1):78-88.Chen Wen, Wei Hongyuan, Zhou Zhijun, et al. Positron emission radiometals⁶⁴Cu, ⁶⁸Ga, ⁸⁶Y and ⁸⁹Zr labeled PET drugs［J］. Journal of Isotopes, 2017, 30(1): 78-88(in Chinese).
［19］Paeng J C, Lee Y S, Lee J S, et al. Feasibility and kinetic characteristics of ⁶⁸Ga-NOTA-RGD PET for in vivo atherosclerosis imaging［J］. Annals of Nuclear Medicine, 2013, 27(9): 847-854.
［20］江雪清,王明召. 潜在放射性药物——镓配合物的研究进展［J］. 化学试剂,2014,36:705-712.Jiang Xueqing, Wang Mingzhao. Progress on potential radiopharmaceuticals-Gallium complexes［J］. Chemical Reagents, 2014, 36: 705-712(in Chinese)..
［21］Asti M, Pietri G D, Fraternali A, et al. Validation of ⁶⁸Ge/⁶⁸Ga generator processing by chemical purification for routine clinical application of ⁶⁸Ga-DOTATOC［J］. Nuclear Medicine & Biology, 2008, 35: 721-724.
［22］Zhernosekov K P, Filosofov D V, Baum R P, et al. Processing of generator-produced ⁶⁸Ga for medical application［J］. Journal of Nuclear Medicine, 2007, 48: 1741-1748.
［23］Prata M I. Gallium-68: a new trend in PET radiopharmacy［J］. Current Radiopharmaceuticals, 2012, 5: 142-149.
［24］Breeman W A P, Blois E D, Chan H S, et al. ⁶⁸Ga-labeled DOTA-peptides and ⁶⁸Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives［J］. Seminars in Nuclear Medicine, 2011, 41: 314-321.
［25］Smith D L, Breeman W A P, Sims-Mourtada J. The untapped potential of Gallium 68-PET: the next wave of ⁶⁸Ga-agents［J］. Applied Radiation & Isotopes, 2013, 76: 14-23.
［26］Hofmann M, Maecke H, Börner A, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand ⁶⁸Ga-DOTATOC: preliminary data［J］. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28: 1751-1757.
［27］Shetty D, Lee Y S, Jeong J M. ⁶⁸Ga-labeled radiopharmaceuticals for positron emission tomography［J］. Nuclear Medicine and Molecular Imaging, 2010, 44: 233-240.
［28］Li D, Zhao X, Zhang L, et al. ⁶⁸Ga-PRGD 2 PET/CT in the evaluation of glioma: A prospective study［J］. Molecular Pharmaceutics, 2014, 11: 3923-3929.
［29］Chen H, Gang N, Hua W, et al. Clinical application of radiolabeled RGD peptides for PET imaging of integrin α_vβ₃［J］. Theranostics, 2016, 6: 78-92.
［30］Li Z B, Chen K, Chen X. ⁶⁸Ga-labeled multimeric RGD peptides for microPET imaging of integrin α_vβ₃ expression［J］. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35: 1100-1108.
［31］Liu Z, Niu G, Shi J, et al. ⁶⁸Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin α_vβ₃ PET imaging［J］. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36: 947-957.
［32］Blom E, Velikyan I, Estrada S, et al. ⁶⁸Ga-Labeling of RGD peptides and biodistribution［J］. International Journal of Clinical & Experimental Medicine, 2012, 5: 165-172.
［33］Dijkgraaf I, Yim C B, Franssen G M, et al. PET imaging of α_vβ₃ integrin expression in tumours with ⁶⁸Ga-labelled mono, di- and tetrameric RGD peptides［J］. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38: 128.
［34］Haukkala J, Laitinen I, Luoto P, et al. ⁶⁸Ga-DOTA-RGD peptide: biodistribution and binding into atherosclerotic plaques in mice［J］. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36: 2058-2067.
［35］Eleni G, Oliver D, Margret S, et al. PET of CXCR4 expression by a ⁶⁸Ga labeled highly specific targeted contrast agent［J］. Journal of Nuclear Medicine, 2011, 52: 1803-1810.
［36］Poschenrieder A, Schottelius M, Schwaiger M, et al. Preclinical evaluation of ［⁶⁸Ga］NOTA-pentixafor for PET imaging of CXCR4 expression in vivo a comparison to ［⁶⁸Ga］pentixafor［J］. EJNMMI Research, 2016, 6: 70-74.
［37］Oliver D, Eleni G, Udo S, et al. PET imaging of CXCR4 receptors in cancer by a new optimized ligand［J］. Chemmedchem, 2011, 6: 1789-1791.
［38］Poty S, Gourni E, Désogère P, et al. AMD3100: a versatile platform for CXCR4 targeting ⁶⁸Ga-based radiopharmaceuticals［J］. Bioconjugate Chemistry, 2016, 27: 752-761.
［39］Hyafil F, Pelisek J, Laitinen I, et al. Imaging the cytokine receptor CXCR4 in atherosclerotic plaques with the radiotracer ⁶⁸Ga pentixafor for PET［J］. Journal of Nuclear Medicine, 2017, 58: 499-506.
［40］Gourni E, Mansi R, Jamous M, et al. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of ⁶⁸Ga- and ⁶⁴Cu-labeled peptides for PET imaging［J］. Journal of Nuclear Medicine, 2014, 55: 1719-1725.
［41］Fani M, Wang X, Nicolas G, et al. Development of new folate-based PET radiotracers: preclinical evaluation of ⁶⁸Ga-DOTA-folate conjugates［J］. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38: 108-119.
［42］Müller C, Vlahov I R, Santhapuram H K R, et al. Tumor targeting using ⁶⁷Ga-DOTA-Bz-folate—investigations of methods to improve the tissue distribution of radiofolates［J］. Nuclear Medicine & Biology, 2011, 38: 715-723.
［43］Fani M, Tamma M L, Nicolas G P, et al. In vivo imaging of folate receptor positive tumor xenografts using novel ⁶⁸Ga-NODAGA-folate conjugates［J］. Molecular Pharmaceutics, 2012, 9: 1136-1145.
［44］Mathias C J, Lewis M R, Reichert D E, et al. Preparation of ⁶⁶Ga- and ⁶⁸Ga-labeled Ga(Ⅲ)-deferoxamine folate as potential folate-receptor-targeted PET radiopharmaceuticals［J］. Nuclear Medicine & Biology, 2003, 30: 725-731.
［45］Zhang J, Lang L, Zhu Z, et al. Clinical translation of an albuminbinding PET radiotracer ⁶⁸Ga-NEB［J］. Journal of Nuclear Medicine, 2015, 56: 1609-1614.
［46］Zhang W, Wu P, Li F, et al. Potential applications of using ⁶⁸Ga-evans blue PET/CT in the evaluation of lymphatic disorder: preliminary observations［J］. Clinical Nuclear Medicine, 2016, 41: 302-308.
［47］Liu Z, Niu G, Wang F, et al. ⁶⁸Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging［J］. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36: 1483-1494.
［48］Liu Z, Yan Y, Liu S, et al.¹⁸F, ⁶⁴Cu, and ⁶⁸Ga-labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer［J］. Bioconjugate Chemistry, 2009, 20: 1016-1025.
［49］Yang Z, Xiong C, Zhang R, et al. Synthesis and evaluation of ⁶⁸Ga-labeled DOTA-2-deoxy-D-glucosamine as a potential radiotracer in μPET imaging［J］. American Journal of Nuclear Medicine and Molecular Imaging, 2012, 2: 499-507.
［50］Notni J, Hermann P, Dregely I, et al. Convenient synthesis of ⁶⁸Ga-labeled gadolinium(Ⅲ) complexes: towards bimodal responsive probes for functional imaging with PET/MRI［J］. Chemistry, 2013, 19: 12602-12606.
［51］Eriksson O, Carlsson F, Blom E, et al. Preclinical evaluation of a ⁶⁸Ga-labeled biotin analogue for applications in islet transplantation［J］. Nuclear Medicine & Biology, 2012, 39: 415-421.
［52］Banerjee S R, Chen Z, Pullambhatla M, et al. Preclinical comparative study of ⁶⁸Ga-Labeled DOTA, NOTA, and HBED-CC chelated radiotracers for targeting PSMA［J］. Bioconjugate Chemistry, 2016, 27: 1447-1455.
［53］Hoigebazar L, Jaemin J, Sooyoung C, et al. Synthesis and characterization of nitroimidazole derivatives for ⁶⁸Ga-labeling and testing in tumor xenografted mice［J］. Journal of Medicinal Chemistry, 2010, 53: 6378-6385.
［54］Fernández S, Dematteis S, Giglio J, et al. Synthesis, in vitro and in vivo characterization of two novel ⁶⁸Ga-labelled 5-nitroimidazole derivatives as potential agents for imaging hypoxia［J］. Nuclear Medicine & Biology, 2013, 40: 273-279.
［55］Percipalle M, Giardina G, Lipari L, et al. Synthesis of novel ⁶⁸Ga-labeled amino acid derivatives for positron emission tomography of cancer cells［J］. Nuclear Medicine & Biology, 2010, 37: 893-902.
［56］Shetty D, Jeong J M, Ju C H, et al. Synthesis and evaluation of macrocyclic amino acid derivatives for tumor imaging by gallium-68 positron emission tomography［J］. Bioorganic & Medicinal Chemistry, 2010, 18: 7338-7347.
［57］Burchardt C, Riss P J, Zoller F, et al. ［⁶⁸Ga］Ga-DO(2)A-(OBu-l-tyr)(2): synthesis, ⁶⁸Ga-radiolabeling and in vitro studies of a novel ⁶⁸Ga-DO(2)A-tyrosine conjugate as potential tumor tracer for PET［J］. Bioorganic & Medicinal Chemistry Letters, 2009, 19: 3498-3501.
［58］Wu Z, Zha Z, Choi S R, et al. New ⁶⁸Ga-PhenA bisphosphonates as potential bone imaging agents［J］. Nuclear Medicine & Biology, 2016, 43: 360-371.
［59］Haubner R, Vera D R, Farshchiheydari S, et al. Development of ⁶⁸Ga-labelled DTPA galactosyl human serum albumin for liver function imaging［J］. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40: 1245-1255.
［60］Haubner R, Schmid A M, Maurer A, et al. ［⁶⁸Ga］NOTA-galactosyl human serum albumin: a tracer for liver function imaging with improved stability［J］. Molecular Imaging & Biology, 2017: 1-8.
［61］Tolmachev V, Velikyan I, Sandstrm M, et al. A HER2-binding affibody molecule labelled with ⁶⁸Ga for PET imaging: direct in vivo comparison with the ¹¹¹In-labelled analogue［J］. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37: 1356-1367.
［62］Lee Y K, Jeong J M, Hoigebazar L, et al. Nanoparticles modified by encapsulation of ligands with a long alkyl chain to affect multispecific and multimodal imaging［J］. Journal of Nuclear Medicine, 2012, 53: 1462-1470.
［63］Frigell J, García I, Gómezvallejo V, et al. ⁶⁸Ga-labeled gold glyconanoparticles for exploring blood–brain barrier permeability: preparation, biodistribution studies, and improved brain uptake via neuropeptide conjugation［J］. Journal of the American Chemical Society, 2014, 136: 449-457.

[1]	黄钱焕;潘栋辉;徐宇平;盛洁;王彦婷;杨敏. ⁶⁸Ge/⁶⁸Ga发生器的临床应用[J]. 同位素, 2017, 30(4): 270-275.
[2]	杨春慧;梁积新;沈浪涛;李洪玉. ⁶⁸Ga标记放射性药物的制备及应用研究进展[J]. 同位素, 2017, 30(3): 209-218.
[3]	韩振义;梁积新;胡骥;罗洪义;卿晶;陈玉清;李光;李洪玉. ⁶⁴Cu标记两种奥曲肽类似物的比较[J]. 同位素, 2016, 29(2): 82-88.
[4]	聂大红;唐刚华. 肿瘤氨基酸代谢PET显像研究进展[J]. 同位素, 2015, 28(4): 214-224.
[5]	张锦明;张晓军;黄德晖;王卉;刘健;田嘉禾. 多发性硬化症显像剂¹¹C-CIC的合成[J]. 同位素, 2015, 28(4): 259-264.
[6]	高霞;张斌;王斌;黄洪波;李新平. ¹⁸F-FDG、¹⁸F-RGD和¹⁸F-FET在LN229脑胶质模型体内生物分布和Micro-PET显像[J]. 同位素, 2015, 28(3): 155-159.
[7]	万卫星;薛杨波;王燕;瞿凌晨;许波华;杨敏. 双示踪剂Micro-PET显像评价大鼠心肌缺血模型[J]. 同位素, 2013, 26(4): 216-221.
[8]	郭先伟 ;黄丽蓉 ;虞善友 ;陆铖 ;王燕 ;颜成龙 ;李新平 ;黄洪波 ;杨敏 . PET显像剂¹⁸F-FLT的合成条件优化[J]. 同位素, 2011, 24(增刊): 76-79.
[9]	王红亮;黄婷婷;梁祥;吴克宁;唐刚华. (N-[¹⁸F]氟甲基)胆碱的半自动合成和无菌型炎症PET显像评价[J]. 同位素, 2011, 24(4): 198-204.
[10]	张锦明 ;徐志红 ;张晓军 ;向晓辉 ;田嘉禾 . 胆碱模块自动化合成¹¹C-carfentanil及Micro PET显像[J]. 同位素, 2011, 24(3): 182-187.
[11]	孙婷 ;王世真 ; 唐刚华 ; 李兆陇 . 1-[¹⁸F]氟代乙基-L-色氨酸的半自动化合成[J]. 同位素, 2010, 23(2): 86-92.
[12]	张锦明;田嘉禾. 国内正电子放射性药物发展现状简介[J]. 同位素, 2006, 19(4): 240-246.

⁶⁸Ga标记药物研究进展

The Research Progress of ⁶⁸Ga Generator and ⁶⁸Ga Radiopharmaceuticals

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 12

编辑推荐

Metrics